Author(s):
Prachi Sanjay Jadhav, Sunil P. Pawar, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani
Email(s):
jadhavprachi.9988@gmail.com
DOI:
10.52711/2231-5675.2026.00051 
Address:
Prachi Sanjay Jadhav1, Sunil P. Pawar2, Amitkumar Rajkumar Dhankani3, Mansi Amitkumar Dhankani3
1Student of P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Dist: Nandurbar, Maharashtra, India.
2Principal of P.S.G.V.P. Mandal’s College of Pharmacy Shahada, Dist: Nandurbar, Maharashtra, India.
3Assistant Professor of P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Dist: Nandurbar, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2026
ABSTRACT:
Favipiravir, a pyrazine carboxamide derivative with broad- spectrum antiviral activity, has gained significant attention for the treatment of RNA viral infections such as influenza and COVID-19. A precise, accurate and robust Ultra- High-Performance Liquid Chromatography (UHPLC) method was developed and validated for the quantitative estimation of favipiravir in bulk and pharmaceutical dosage forms. Chromatographic separation was performed on a reverse-phase column using an optimized mobile phase under isocratic conditions at a controlled flow rate, with UV detection at a suitable wavelength. The retention time of favipiravir was found to be consistent with good peak symmetry. The method was validated in accordance with ICH Q2(R1) guidelines. Linearity was observed over a suitable concentration range with a correlation coefficient (R²) greater than 0.999. The method demonstrated acceptable accuracy with percentage recovery within 98–102% and precision with %RSD less than 2%. The LOD and LOQ values indicated adequate sensitivity of the method. Robustness studies confirmed the reliability under small deliberate variations in method parameters. The validated method was successfully applied for the assay of favipiravir in marketed tablet formulations, showing no interference from excipients. The developed UHPLC method is simple, rapid, and suitable for routine pharmaceutical analysis.
Cite this article:
Prachi Sanjay Jadhav, Sunil P. Pawar, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani. Prachi Sanjay Jadhav, Sunil P. Pawar, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):332-6. doi: 10.52711/2231-5675.2026.00051
Cite(Electronic):
Prachi Sanjay Jadhav, Sunil P. Pawar, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani. Prachi Sanjay Jadhav, Sunil P. Pawar, Amitkumar Rajkumar Dhankani, Mansi Amitkumar Dhankani. Asian Journal of Pharmaceutical Analysis. 2026; 16(4):332-6. doi: 10.52711/2231-5675.2026.00051 Available on: https://www.ajpaonline.com/AbstractView.aspx?PID=2026-16-4-13
REFERENCES:
1. Y. Furuta, B. B. Gowen, K. Takahashi, et. al. Antiviral Res. 2013; 100(2): 446– 454.
2. DeClercq, E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem. Asian J. 2019;14(22): 3962–8.
3. Delang, L.; Abdelnabi, R.; Neyts, J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85–94.
4. Y. Furuta, T. Komeno, and T. Nakamura, Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2017; 93(7): 449– 463.
5. D. Sissoko, C. Laouenan, E. Folkesson, et. al., PLoS Med. 2016; 13(3): e1001967.
6. L. Dong, S. Hu, and J. Gao, Drug Discov. Ther. 2020; 14(1): 58– 60.
7. D. Clercq, Chem. Asian J. 2019; 14(22): 3962– 3968.
8. L. Delang, R. Abdelnabi, and J. Neyts, Antiviral Res. 2018; 153: 85– 94.
9. https://go.drugbank.com/drugs/DB12466
10. Singh RK, Rathnam MV, Singh SJ, Vegesna RV. Determination of Camylofin dihydrochloride and Nimesulide in Pharmaceutical Preparation by Gas chromatography. American Journal of Analytical Chemistry. 2011; 2(8): 944.
11. Natesan S, Thanasekaran D, Krishnaswami V, Ponnusamy C. Improved RP-HPLC method for the simultaneous estimation of Tranexamic acid and mefenamic acid in tablet dosage form. Pharm. Anal. Acta. 2011; 2(1): 115.
12. Zhang LJ, Yao YM, Sun JJ, Chen J, Jia XF. An LC–MS/MS Method for Simultaneous Quantification of Seven Anti-HIV Medicines in Plasma of HIV-infected Patients. Pharm Anal Acta. 2010; 1(1): 1.
13. Rajender G, Narayana NG. Liquid Chromatography-Tandem Mass Spectrometry Method for Determination of Paclitaxel in Human Plasma. Pharm Anal Acta. 2010; 1: 101.
14. Sharma HK, Jain N, Jain SK. Development of spectrophotometric Method for quantitative estimation of Amlodipine besylate, Olmesartan medoxomil and hydrochlorothiazide in tablet dosage Form. Pharm Anal Acta. 2011; 2(126): 2.
15. Bliesner D.M., Validating Chromatographic Methods, John Wiley & Sons, Inc. 2006; 88-92.
16. A Guide to Validation in HPLC Based on the Work of G.M. Hearn Perkin Elmer. R.A. van Iterson Drenthe College Emmen Holland for www.standardbase.com. Accessed April 05, 2013.
17. Taskin D. Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation. Clin Exp Health Sci 2022; 12: 648-652. htpps://doi.org/10.33808/clinexphealthsci.992869.
18. Snyder L. R., Kirkland J.J., RP-HPLC method development, Willey Interscience Publication, New York, 2nd Edition, 1997, 296.
19. Ahuja Sand Scypinski S, Handbook of Modern Pharmaceutical Analysis, Elsevier Academic Press London, 1st edition. Volume-11, 2001, 1-3.
20. ICH Harmonized Tripartite Guidelines, Validation of Analytical Procedure’: Text and Methodology, Q2 (R1), Current step 4 version; 27 oct 1994.
21. Ravisankar P., Divya B., Sailu A.B., Meelima K., A. Viswanath, P. Srinivasa Babu, RP- HPLC Method for Determination of favipiravir (RdRp of RNA Viruses) in Pharmaceutical Dosage Form, Current Trends in Biotechnology and Pharmacy. 2022; 16: 60-69.
22. Ramadoss K, Meerasa SS, Satyapal AK, Vijayakumar A, Venugopal V. Quantitative analysis of favipiravir in bulk and pharmaceutical dosage forms using UV visible spectrophotometer. J of Med Pharma and Allied Sciences. 2023 April; 12(2): 4410.
23. M. S. Kalshetti, Sagar G. Adlinge, Development and Validation of HPLC Method for Quqntificqtion of Favipiravir in Tablet, Research Journal of Pharmacy and Technology. 2022; 15(3); 1319-2. htpps://doi.org/10.52711/0974-360X.2022.00220.
24. Taskin D. Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation. Clin Exp Health Sci. 2022; 12: 648-652.
25. htpps://doi.org/10.33808/clinexphealthsci.992869.
26. Sayyed Nazifa Sabir Ali, Analytical Method Development and Validation and Forced Degradation Stability-Indicating Studies of Favipiravir by RP-HPLC and UV in Bulk and Pharmaceutical Dosage Form. J of Pharm Res Intl. 2021; 33(48B): 254-271.